

Firm News | July 24, 2023

Troutman Pepper's Capital Markets Practice Achieves Top 2023 H1 League Table Rankings

RELATED PROFESSIONALS

[David I. Meyers](#) | [Thomas M. Rose](#) | [Shona Smith](#)

NEW YORK – Troutman Pepper advised in more than 50 capital markets transactions in the first half of 2023 with an overall deal value of more than \$13 billion. While transactions spanned across the United States, the firm saw significant success in Canadian cross-border deals.

“We are incredibly grateful for a busy first quarter, as it gives us opportunities to continue to demonstrate how we provide our clients with timely cross-border services and guide them through complex transactions,” said Partner Tom Rose. “It is always satisfying and reassuring to see our rankings each year, but we remained focused on helping our clients reach their business goals through their most important deals or critical day-to-day matters.”

Notably, the firm's Canadian Practice Group improved its ranking in both the manager and issuer legal advisor categories for Canada equity and equity-related deals. Rankings:

[Thomson Reuters/Refinitiv – Global Capital Markets Legal Review H1 2023](#)

Canada Equity & Equity-related (CAL4) Issuer Legal Advisor

#1 ranked firm (up from #2 in 2022)

Canada Equity & Equity-related (CAL4) Manager Legal Advisor

#5 ranked firm (up from #8 in 2022)

[Bloomberg Global Legal Adviser League Tables H1 2023](#)

Canada Equity Offerings: Legal Adviser – Issuer Ranked by Deal Count

#2 ranked firm (#1 US-based firm)

Canada Equity Offerings: Legal Adviser – Manager Ranked by Deal Count

#5 ranked firm (#1 US-based firm)

Canada Equity IPO: Legal Adviser – Issuer Ranked by Volume

#5 ranked firm

Canada Equity IPO: Legal Adviser – Issuer Ranked by Deal Count

#5 ranked firm

Canada Equity and Equity Linked: Legal Adviser – Issuer Ranked by Deal Count

#2 ranked firm (#1 US-based firm)

Canada Equity and Equity Linked: Legal Adviser – Manager Ranked by Deal Count

#5 ranked firm (#1 US-based firm)

Canada Equity, Equity Linked & Preferred: Legal Adviser – Issuer Ranked by Deal Count

#2 ranked firm (#1 US-based firm)

Canada Equity, Equity Linked & Preferred: Legal Adviser – Manager Ranked by Deal Count

#5 ranked firm

Clients turn to Troutman Pepper for comprehensive, global counsel on investment and operational activities and decisions. The firm handles the gamut of equity and debt transactions, from IPOs and first-time listings to investment-grade debt offerings to equity-linked and preferred and hybrid securities. Troutman Pepper advises on all phases of capital market deals, including structuring and governance; timing and tax planning; negotiating underwriting or purchase agreements, trust indentures, and other documents; preparing registration statements and prospectus/offering circulars; and regulatory and corporate law.

Troutman Pepper's Canadian Practice Group represents Canadian companies with respect to their U.S. legal needs. The Group includes lawyers with experience in the areas of securities and corporate finance; mergers and acquisitions; energy regulation; energy trading; intellectual property; immigration; tax; government contracts; and complex litigation. The team regularly acts as counsel on U.S. public and private equity and debt offerings for Canadian issuers, Canadian and U.S. underwriters or agents and Canadian and U.S. investors, including assisting Canadian companies with U.S. exchange listings and U.S. periodic reporting obligations.

About Troutman Pepper

Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm's litigation, transactional, and regulatory practices advise a diverse client base, from startups to multinational enterprises. The firm provides sophisticated legal solutions to clients' most pressing business challenges, with depth across industry sectors, including energy, financial services, health sciences, insurance, and private equity, among others. Learn more at troutman.com.

RELATED INDUSTRIES + PRACTICES

- Capital Markets
- Corporate
- Health Care + Life Sciences